- SK pharmteco has announced a brand unification initiative to integrate its global entities under a single brand.
- The rebranding effort aims to enhance collaboration and streamline service delivery across its extensive CDMO portfolio.
SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industries, has unveiled a brand unification strategy, consolidating its worldwide operations under a single name. The initiative merges the capabilities of SK biotek, SK biotek Ireland, AMPAC Fine Chemicals, AMPAC Analytical, Yposkesi, and the Center for Breakthrough Medicines.
The rebranding aims to establish SK pharmteco as a powerhouse in the pharmaceutical and cell and gene therapy industries. The unified organisation now offers end-to-end solutions, ranging from early-stage development and analytical testing to commercial manufacturing. CEO Joerg Ahlgrimm emphasised, “By uniting under the SK pharmteco banner, we create a stronger, more streamlined organisation that delivers a seamless experience for our clients.”
A key aspect of the rebranding includes the launch of a revamped website and updated visual identity to reflect the company’s commitment to innovation and collaboration. Liza Rivera, Vice President of Marketing & Communications, remarked, “Our rebrand aligns our identity with our mission to deliver transformative medicines and exceptional service to our customers.”
The initiative also strengthens SK pharmteco’s global footprint, with strategically located facilities across North America, Europe, and Asia, ensuring efficient project management and close client collaboration.
The company’s expanded service portfolio includes process development for small molecules, cell and gene therapy manufacturing, and comprehensive analytical development services. This expansive network enables streamlined project management and fosters strong collaboration with clients on a global scale.